Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the commercial launch of Denavir® (penciclovir cream) 1% in Canada. Denavir is a topical antiviral prescription medication indicated for the treatment of herpes labialis, also known as cold sores, in adults. This is the only topical antiviral product available by prescription for treating this condition.
